{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-331516","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2026-08-04T11:02:52+00:00","discovered_at":"2026-08-04T11:05:00.386483+00:00","generated_at":"2026-08-04T11:05:18.874465+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Larimar Q2 net loss $32.8M; nomlabofusp BLA rolling submission underway","bullets":["Net loss $32.8M ($0.30/sh) vs $26.2M ($0.41/sh) in Q2 2025; cash $156.3M, runway into Q3 2027.","Open-label study: 43 participants dosed; 82% achieved skin FXN above asymptomatic carriers at 6 months, 100% at 1 year.","mFARS benefit of 2.6 points at 1 year vs natural history; no withdrawals from injection site reactions.","Rolling BLA for accelerated approval started; completion expected 2H 2026; confirmatory Phase 3 first patient dosing expected Q3 2026.","Targeting mid-2027 launch if approved; FDA agreed FXN as surrogate endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-331516","json":"https://secwatch.observer/filing/0001193125-26-331516.json","markdown":"https://secwatch.observer/filing/0001193125-26-331516.md","text":"https://secwatch.observer/filing/0001193125-26-331516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/0001193125-26-331516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:05:18.874465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}